Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
Abstract Background The low response rate of anti-PD-1 monoclonal antibodies (mAbs) in hepatocellular carcinoma (HCC) requires the development of combination immunotherapy strategies to improve their efficacy. This study aimed to use LAG-3-targeted PET imaging to monitor the efficacy of anti-PD-1 mA...
Saved in:
| Main Authors: | Zhen Quan, Yu Gao, Bo Sun, Yiwan Guo, Ziwei Jin, Na Hao, Dawei Jiang, Chuansheng Zheng, Xin Li, Quan Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-025-00820-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model
by: Felipe F. Lamenza, et al.
Published: (2025-12-01) -
Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value
by: Madonna I. William, et al.
Published: (2025-06-01) -
PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer
by: Yifan Wu, et al.
Published: (2025-08-01) -
PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia
by: O. N. Selyutina, et al.
Published: (2023-12-01) -
Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)